BIVDA Press Releases

01Sep

Press Release - BIVDA joins call to urge Prime Minister to protect charity research

For immediate release

BIVDA joins call to urge Prime Minister to protect charity research

BIVDA has joined over 30 top pharmaceutical, IVD and health tech bodies who have signed an open letter to the Prime Minister urging Government to provide financial support for medical research charities. The Life Sciences-Charity Partnership Fund, developed by the Association of Medical Research Charities (AMRC), has support from the likes of AstraZeneca, Roche and Eli Lilly. All are calling on Government to bridge the projected £310 million shortfall in charity research investment.

The open letter urges the Prime Minister, Boris Johnson, to provide three years of matched funding via the proposed fund to protect the vital and unique contributions of charity research to the UK’s health and economy. Charities provide significant R&D investment in the UK, spending £14 billion on research since 2008. They account for half of publicly funded medical research nationally and are crucial to attracting private investment, stimulating over £196 million in further funding from the private sector since 2005. The suspension of many fundraising activities and shop closures due to COVID-19 has had an immediate and severe impact on charities’ income, forcing them to cut their research spend by 41% over the next year.

The letter warns that this will have a knock-on effect on essential private R&D investment, posing an even greater risk to Government’s goal to increase R&D expenditure to 2.4% of GDP by 2027.

Doris-Ann Williams, Chief Executive of BIVDA said;

“The work of medical research charities is vital for promoting complex, early stage research into drugs, medical devices and IVDs that help to treat and diagnose patients. The Life Sciences Charity Partnership Fund would go a long way to support this vital work in the future.“

Aisling Burnand MBE, CEO of the Association of Medical Research Charities said:

“The UK is fortunate to have a range of vibrant medical research charities that add to the country’s life sciences R&D funding mix and this sector must be protected in the aftermath of COVID-19. Charity research provides the foundations for commercial research. You cannot support the latter without the former. By investing in charity-funded research, Government can help medical research charities deliver a better future for patients across the UK, protect the UK’s research skills and capabilities and contribute to economic growth.”

 

ENDS

 

You can find a copy of the letter attached to this web page. 

 

For more information please contact BIVDA External Affairs Manager Jon Harrison on jonh@bivda.org.uk

Attachments

  1. OpenlettertoPrimeMinister.pdf 9/1/2020 10:16:50 AM

Related

BIVDA comment on the Health and Social Care Committee’s report into Antimicrobial resistance

Today the Health and Social Care Committee has published its report on Antimicrobial resistance.

Read More >

NICE launches HealthTech Connect

NICE has launched HealthTech Connect, an online system for identifying and supporting health technol...

Read More >

BIVDA Response to Cancer Research UK Report on Pathology Services

Cancer Research UK have today (23 November 2016) published a report which finds that UK pathology se...

Read More >

Member Press Release - UK COVID-19 rapid antibody tests approved for professional use

The COVID-19 rapid antibody test, developed by Abingdon Health, the medical device manufacturer lead...

Read More >

PwC analysis highlights economic footprint of UK Life Sciences

The productivity of the UK’s Life Sciences sector is more than double the UK average, says a new re...

Read More >

BIVDA response to Parliament’s vote on the Brexit deal

Doris-Ann Williams, Chief Executive of BIVDA, comments on tonight's vote

Read More >